389 related articles for article (PubMed ID: 21746763)
1. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
2. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
3. Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids.
Sapay N; Cabannes E; Petitou M; Imberty A
Biopolymers; 2012 Jan; 97(1):21-34. PubMed ID: 21780097
[TBL] [Abstract][Full Text] [Related]
4. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.
Bisio A; Mantegazza A; Urso E; Naggi A; Torri G; Viskov C; Casu B
Semin Thromb Hemost; 2007 Jul; 33(5):488-95. PubMed ID: 17629845
[TBL] [Abstract][Full Text] [Related]
5. Multi-faceted substrate specificity of heparanase.
Peterson SB; Liu J
Matrix Biol; 2013 Jun; 32(5):223-7. PubMed ID: 23499529
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N
J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902
[TBL] [Abstract][Full Text] [Related]
8. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
10. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
11. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
13. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate.
Escobar Galvis ML; Jia J; Zhang X; Jastrebova N; Spillmann D; Gottfridsson E; van Kuppevelt TH; Zcharia E; Vlodavsky I; Lindahl U; Li JP
Nat Chem Biol; 2007 Dec; 3(12):773-8. PubMed ID: 17952066
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of activation of human heparanase investigated by protein engineering.
Nardella C; Lahm A; Pallaoro M; Brunetti M; Vannini A; Steinkühler C
Biochemistry; 2004 Feb; 43(7):1862-73. PubMed ID: 14967027
[TBL] [Abstract][Full Text] [Related]
15. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence.
Okada Y; Yamada S; Toyoshima M; Dong J; Nakajima M; Sugahara K
J Biol Chem; 2002 Nov; 277(45):42488-95. PubMed ID: 12213822
[TBL] [Abstract][Full Text] [Related]
16. Heparanase, heparin and the coagulation system in cancer progression.
Vlodavsky I; Ilan N; Nadir Y; Brenner B; Katz BZ; Naggi A; Torri G; Casu B; Sasisekharan R
Thromb Res; 2007; 120 Suppl 2():S112-20. PubMed ID: 18023704
[TBL] [Abstract][Full Text] [Related]
17. Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase.
Lai NS; Simizu S; Morisaki D; Muroi M; Osada H
Exp Cell Res; 2008 Sep; 314(15):2834-45. PubMed ID: 18662687
[TBL] [Abstract][Full Text] [Related]
18. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.
Parish CR; Freeman C; Brown KJ; Francis DJ; Cowden WB
Cancer Res; 1999 Jul; 59(14):3433-41. PubMed ID: 10416607
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations of CXCL-8 and its interactions with a receptor peptide, heparin fragments, and sulfated linked cyclitols.
Gandhi NS; Mancera RL
J Chem Inf Model; 2011 Feb; 51(2):335-58. PubMed ID: 21299226
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site.
Alberdi E; Hyde CC; Becerra SP
Biochemistry; 1998 Jul; 37(30):10643-52. PubMed ID: 9692954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
